Condition: Esophageal Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Gastroesophageal Junction Carcinoma · Sponsor: VA Office of Research and Development
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.
This description comes directly from the study's public registry record.
David H Wang, MD PhD · davidh.wang@va.gov
Always discuss trial participation with your own doctor first.
| VA Palo Alto Health Care System, Palo Alto, CA | Palo Alto, California, United States | Recruiting |
| VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor, Michigan, United States | Recruiting |
| Durham VA Medical Center, Durham, NC | Durham, North Carolina, United States | Recruiting |
| VA Portland Health Care System, Portland, OR | Portland, Oregon, United States | Recruiting |
| VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX | Dallas, Texas, United States | Recruiting |
| Michael E. DeBakey VA Medical Center, Houston, TX | Houston, Texas, United States | Recruiting |
| VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05563766